Please assess the completion status of the following clinical trial:

Trial Title: Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~DISEASE CHARACTERISTICS:~* Histologically confirmed primary infiltrating adenocarcinoma of the breast~  * Confirmed by core needle biopsy or incisional biopsy or surgery~ * Experienced grade 1 cardiac toxicity during prior anthracycline-based chemotherapy~ * At least 2 cycles same anthracycline based chemotherapy are needed~Exclusion Criteria:~* Accumulated dose of EPI ≥1000mg/m2,ADM≥550mg/m2~* With the following risk factors: Uncontrolled or severe cardiovascular disease (e.g., myocardial infarction within the past 6 months, congestive heart failure treated with medications, or uncontrolled hypertension); Prior or Concurrent radiation to heart~* Pregnant or nursing~* Other currently active malignancy except nonmelanoma skin cancer~* Uncontrolled or severe bleeding,diarrhea,intestinal obstruction~* Grade 2 or more Cardiac Toxicity (CTC AE3.0)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- control arm (Type: NO_INTERVENTION): anthracycline chemotherapy only
- low dose dexrazoxane group (Type: EXPERIMENTAL): anthracycline chemotherapy plus low dose dexrazoxane(10:1)
- middle dose dexrazoxane group (Type: EXPERIMENTAL): anthracycline chemotherapy plus middle dose dexrazoxane(15:1)

Based on this trial design, predict the completion outcome and termination type (if applicable).